Activity Description
The prevention of thromboembolic complications remains a continuous clinical challenge for the dedicated team of multidisciplinary clinicians managing Atrial Fibrillation (AF) patients. As the left atrial appendage (LAA) is the most common source of cardioembolic strokes, it is imperative to adopt optimal procedural strategies to occlude the LAA to improve outcomes in patients at a heightened risk of systemic thromboembolism who are contraindicated for oral anticoagulation therapy or seek a non-pharmacologic alternative.
The world-renowned faculty evaluate LAA closure (LAAC) vs. novel oral anticoagulant (NOAC) outcomes data, PINNACLE-FLX study results, WATCHMAN FLX implantation techniques, and examine the most effective post-LAAC antithrombotic strategy.
Agenda
Click on session titles within the agenda to view that segment of the activity.
| Agenda | ||
 |
LAAC vs NOACs: PRAGUE-17 Outcomes Vivek Reddy, MD |
|
 |
LAAC vs NOACs: A propensity-score matched analyses Prof. Jens Erik Nielsen-Kudsk, MD, DMSc |
|
 |
WATCHMAN FLX Implantation: Similarities/Differences from Implantation of the Standard WATCHMAN Device Shephal Doshi, MD |
|
 |
WATCHMAN FLX Outcomes: Results of PINNACLE-FLX Saibal Kar, MD, FACC, FSCAI |
|
 |
What is the Best Post-LAAC Antithrombotic Strategy? Andrea Natale, MD, FACC, FHRS, FESC |
|
 |
Panel Discussion with Q&A Session Moderator: Vivek Reddy, MD Panel: Prof. Jens Erik Nielsen-Kudsk, MD, DMSc, Shephal Doshi, MD, Saibal Kar, MD, FACC, FSCAI, Andrea Natale, MD, FACC, FHRS, FESC |
|
Educational grant support provided by:
Boston Scientific
Joint Providership
MediaSphere Medical, LLC and Ciné-Med
Faculty
|
Program Directors |
||
Vivek Reddy, MD |
|
|
|
Faculty |
||
|
|
|
|
|
|
|
Shephal Doshi, MD 
Prof. Jens Erik Nielsen-Kudsk, MD, DMSc
Saibal Kar, MD, FACC, FSCAI 
Andrea Natale, MD, FACC, FHRS, FESC